Hamid Ahmadieh1, Siamak Moradian, Mohsen Malihi. 1. Department of Ophthalmology, Ophthalmic Research Center, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Boostan 9 St., Pasdaran Ave., Tehran, 16666, Iran. hahmadieh@hotmail.com
Abstract
PURPOSE: To report the rapid regression of extensive retinovitreal neovascularization following the administration of a single dose of intravitreal bevacizumab. METHODS: A 60-year-old woman presented with recurrent vitreous hemorrhage originating from active retinovitreal neovascularization secondary to branch retinal vein occlusion. The neovascular tissue remained active despite multiple sessions of laser therapy. Intravitreal injection of 1.25 mg bevacizumab was performed. RESULTS: Rapid regression of the retinovitreal neovascularization, a marked reduction in retinal vein engorgement, and visual improvement was observed 1 week after the intervention CONCLUSION: Intravitreal bevacizumab can result in the rapid and dramatic regression of retinovitreal neovascularization refractory to previous laser photocoagulation.
PURPOSE: To report the rapid regression of extensive retinovitreal neovascularization following the administration of a single dose of intravitreal bevacizumab. METHODS: A 60-year-old woman presented with recurrent vitreous hemorrhage originating from active retinovitreal neovascularization secondary to branch retinal vein occlusion. The neovascular tissue remained active despite multiple sessions of laser therapy. Intravitreal injection of 1.25 mg bevacizumab was performed. RESULTS: Rapid regression of the retinovitreal neovascularization, a marked reduction in retinal vein engorgement, and visual improvement was observed 1 week after the intervention CONCLUSION: Intravitreal bevacizumab can result in the rapid and dramatic regression of retinovitreal neovascularization refractory to previous laser photocoagulation.
Authors: Anthony P Adamis; Michael Altaweel; Neil M Bressler; Emmett T Cunningham; Matthew D Davis; Mauro Goldbaum; Christine Gonzales; David R Guyer; Katz Barrett; Manju Patel Journal: Ophthalmology Date: 2005-12-15 Impact factor: 12.079
Authors: Robert L Avery; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust Journal: Ophthalmology Date: 2006-02-03 Impact factor: 12.079
Authors: Walid F Abdallah; Hitenkumar Patel; Edward G Grant; Bruno Diniz; Gerald J Chader; Mark S Humayun Journal: Invest Ophthalmol Vis Sci Date: 2012-10-05 Impact factor: 4.799
Authors: Abdullah Al-Kharashi; Tural Galbinur; Efrem D Mandelcorn; Rajeev H Muni; Mir Nabavi; Peter J Kertes Journal: Saudi J Ophthalmol Date: 2016-10-29